EE200300227A - P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid - Google Patents
P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendidInfo
- Publication number
- EE200300227A EE200300227A EEP200300227A EEP200300227A EE200300227A EE 200300227 A EE200300227 A EE 200300227A EE P200300227 A EEP200300227 A EE P200300227A EE P200300227 A EEP200300227 A EE P200300227A EE 200300227 A EE200300227 A EE 200300227A
- Authority
- EE
- Estonia
- Prior art keywords
- kinase
- treatment
- methods
- compounds useful
- related conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24987700P | 2000-11-17 | 2000-11-17 | |
US31056101P | 2001-08-07 | 2001-08-07 | |
PCT/US2001/049982 WO2002040486A2 (en) | 2000-11-17 | 2001-11-07 | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200300227A true EE200300227A (et) | 2003-10-15 |
Family
ID=26940426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200300227A EE200300227A (et) | 2000-11-17 | 2001-11-07 | P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP1363910B1 (es) |
JP (1) | JP2004522713A (es) |
KR (1) | KR100847605B1 (es) |
CN (1) | CN1622946A (es) |
AR (1) | AR032637A1 (es) |
AT (1) | ATE318820T1 (es) |
AU (2) | AU3276002A (es) |
BG (1) | BG107750A (es) |
BR (1) | BR0115446A (es) |
CA (1) | CA2429628A1 (es) |
CY (1) | CY1105250T1 (es) |
CZ (1) | CZ20031370A3 (es) |
DE (1) | DE60117607T2 (es) |
DK (1) | DK1363910T3 (es) |
EE (1) | EE200300227A (es) |
ES (1) | ES2259051T3 (es) |
GE (1) | GEP20063915B (es) |
HK (1) | HK1057555A1 (es) |
HR (1) | HRP20030485A2 (es) |
HU (1) | HUP0303897A2 (es) |
IL (1) | IL155570A0 (es) |
IS (1) | IS6816A (es) |
MX (1) | MXPA03004290A (es) |
MY (1) | MY127066A (es) |
NO (1) | NO20032229L (es) |
NZ (1) | NZ525334A (es) |
PE (1) | PE20020819A1 (es) |
PL (1) | PL366376A1 (es) |
PT (1) | PT1363910E (es) |
SK (1) | SK5402003A3 (es) |
WO (1) | WO2002040486A2 (es) |
YU (1) | YU37903A (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
ATE330608T1 (de) | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
CA2452392A1 (en) | 2001-06-29 | 2003-01-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
WO2003002106A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitions for treating allergic diseases |
WO2003002105A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating bone loss |
WO2003003006A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
SI1474395T1 (sl) | 2002-02-12 | 2008-02-29 | Smithkline Beecham Corp | Nikotinamidni derivati, uporabni kot inhibitorji p38 |
CA2476012C (en) | 2002-02-14 | 2011-04-19 | Pharmacia Corporation | Substituted pyridinones as modulators of p38 map kinase |
US6900208B2 (en) | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
US7388009B2 (en) * | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
EP1503996B1 (en) | 2002-04-23 | 2008-12-24 | Bristol-Myers Squibb Company | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
PL219736B1 (pl) * | 2002-04-23 | 2015-07-31 | Bristol Myers Squibb Co | Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie |
US6933386B2 (en) | 2002-07-19 | 2005-08-23 | Bristol Myers Squibb Company | Process for preparing certain pyrrolotriazine compounds |
TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
WO2004013145A1 (en) * | 2002-08-02 | 2004-02-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
PT1581535E (pt) * | 2003-01-09 | 2007-12-12 | Astellas Pharma Inc | Derivados de pirrolopiridazina |
JP2006516653A (ja) * | 2003-02-05 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤ピロロトリアジンの製造方法 |
GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308201D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
US7652044B2 (en) | 2003-06-03 | 2010-01-26 | Novartis A.G. | P-38 inhibitors |
SI2298743T1 (sl) | 2003-06-26 | 2012-12-31 | Novartis Ag | Inhibitorji p38-kinaze na osnovi 5-ÄŤlenskih heterociklov |
WO2005012241A2 (en) | 2003-07-25 | 2005-02-10 | Novartis Ag | p-38 KINASE INHIBITORS |
GB0318814D0 (en) | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
US7102001B2 (en) * | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
RU2006126791A (ru) * | 2003-12-23 | 2008-01-27 | Новартис АГ (CH) | Бициклические гетероциклические ингибиторы р-38 киназы |
US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
UY28931A1 (es) * | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
US7102002B2 (en) * | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7102003B2 (en) | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
PE20060421A1 (es) | 2004-08-12 | 2006-06-01 | Bristol Myers Squibb Co | Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa |
US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
CN101035791B (zh) * | 2004-10-26 | 2010-12-08 | 诺瓦提斯公司 | 作为c-JUN N末端激酶(JNK)和P-38激酶的抑制剂的吡咯并[1,2-D][1,2,4]三嗪 |
US7402582B2 (en) * | 2005-07-01 | 2008-07-22 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
US7405213B2 (en) * | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US8063208B2 (en) | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
CN101535312B (zh) * | 2006-11-03 | 2013-04-24 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
US8268998B2 (en) | 2006-11-03 | 2012-09-18 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
AR074830A1 (es) | 2008-12-19 | 2011-02-16 | Cephalon Inc | Pirrolotriazinas como inhibidores de alk y jak2 |
WO2010120963A1 (en) * | 2009-04-16 | 2010-10-21 | Bristol-Myers Squibb Company | Tablet formulation for p38 inhibitor and method |
MX2012013824A (es) * | 2010-05-28 | 2013-03-12 | Biocryst Pharm Inc | Compuestos heterociclicos como inhibidores de cinasa janus. |
CN103012439B (zh) * | 2012-11-15 | 2015-03-11 | 沈阳药科大学 | 苯甲酰基取代的噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用 |
US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
US9458164B2 (en) * | 2013-03-11 | 2016-10-04 | Bristol-Myers Squibb Company | Pyrrolopyridazines as potassium ion channel inhibitors |
ES2616025T3 (es) * | 2013-03-11 | 2017-06-09 | Bristol-Myers Squibb Company | Pirrolotriazinas como inhibidores de canales de iones potasio |
US9737542B2 (en) | 2013-10-11 | 2017-08-22 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
WO2015081783A1 (zh) * | 2013-12-06 | 2015-06-11 | 江苏奥赛康药业股份有限公司 | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途 |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
CA3077499C (en) | 2017-10-05 | 2021-09-21 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN108516977A (zh) * | 2018-07-10 | 2018-09-11 | 刘凤娟 | 一种用于治疗恶性肿瘤的map激酶抑制剂的合成方法 |
CN112028892B (zh) * | 2020-07-29 | 2022-12-16 | 天津全和诚科技有限责任公司 | 4-氨基-吡咯并三嗪衍生物在制备抗肺纤维化制剂中的应用 |
CN112094219B (zh) * | 2020-09-10 | 2022-08-05 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2163399A1 (en) * | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
WO1999024033A1 (en) * | 1997-11-12 | 1999-05-20 | Shionogi & Co., Ltd. | Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
DK1183033T3 (da) * | 1999-05-21 | 2006-06-06 | Bristol Myers Squibb Co | Pyrrolotriazininhibitorer af kinaser |
-
2001
- 2001-11-07 NZ NZ525334A patent/NZ525334A/en unknown
- 2001-11-07 CN CNA018189970A patent/CN1622946A/zh active Pending
- 2001-11-07 AT AT01992298T patent/ATE318820T1/de not_active IP Right Cessation
- 2001-11-07 AU AU3276002A patent/AU3276002A/xx active Pending
- 2001-11-07 DE DE60117607T patent/DE60117607T2/de not_active Expired - Lifetime
- 2001-11-07 EP EP01992298A patent/EP1363910B1/en not_active Expired - Lifetime
- 2001-11-07 CZ CZ20031370A patent/CZ20031370A3/cs unknown
- 2001-11-07 ES ES01992298T patent/ES2259051T3/es not_active Expired - Lifetime
- 2001-11-07 YU YU37903A patent/YU37903A/sh unknown
- 2001-11-07 BR BR0115446-0A patent/BR0115446A/pt not_active IP Right Cessation
- 2001-11-07 PL PL01366376A patent/PL366376A1/xx not_active Application Discontinuation
- 2001-11-07 IL IL15557001A patent/IL155570A0/xx unknown
- 2001-11-07 AU AU2002232760A patent/AU2002232760B2/en not_active Ceased
- 2001-11-07 PT PT01992298T patent/PT1363910E/pt unknown
- 2001-11-07 SK SK540-2003A patent/SK5402003A3/sk unknown
- 2001-11-07 KR KR1020037006661A patent/KR100847605B1/ko not_active IP Right Cessation
- 2001-11-07 GE GE5243A patent/GEP20063915B/en unknown
- 2001-11-07 MX MXPA03004290A patent/MXPA03004290A/es active IP Right Grant
- 2001-11-07 DK DK01992298T patent/DK1363910T3/da active
- 2001-11-07 HU HU0303897A patent/HUP0303897A2/hu unknown
- 2001-11-07 CA CA002429628A patent/CA2429628A1/en not_active Abandoned
- 2001-11-07 EE EEP200300227A patent/EE200300227A/xx unknown
- 2001-11-07 JP JP2002543494A patent/JP2004522713A/ja active Pending
- 2001-11-07 WO PCT/US2001/049982 patent/WO2002040486A2/en active IP Right Grant
- 2001-11-13 MY MYPI20015207A patent/MY127066A/en unknown
- 2001-11-16 AR ARP010105381A patent/AR032637A1/es unknown
- 2001-11-16 PE PE2001001141A patent/PE20020819A1/es not_active Application Discontinuation
-
2003
- 2003-04-21 BG BG107750A patent/BG107750A/bg unknown
- 2003-05-14 IS IS6816A patent/IS6816A/is unknown
- 2003-05-16 NO NO20032229A patent/NO20032229L/no not_active Application Discontinuation
- 2003-06-16 HR HR20030485A patent/HRP20030485A2/hr not_active Application Discontinuation
-
2004
- 2004-01-19 HK HK04100424A patent/HK1057555A1/xx not_active IP Right Cessation
-
2006
- 2006-06-01 CY CY20061100698T patent/CY1105250T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200300227A (et) | P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid | |
DE69910368D1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen | |
NO20015650D0 (no) | Pyrrolotriazin-inhibitorer for kinaser | |
EE200300459A (et) | Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena | |
ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
ID22982A (id) | PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38 | |
DE60023268D1 (de) | INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTE DES CYCLINES et IkB-alpha | |
NO20021382L (no) | Fremgangsmåter og mikroorganismer for fremstilling av panto- forbindelser | |
EE200200715A (et) | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena | |
EE200100659A (et) | Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks | |
EE200200576A (et) | Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena | |
EE200100717A (et) | Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks | |
EE200200461A (et) | Pteridiiniühendid psoriaasi raviks | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
NO20023482D0 (no) | Fremgangsmåte for behandling av stoffmisbruk | |
ATE273276T1 (de) | Cyclobutendion-derivate zur behandlung von artherosclerose | |
WO2002076396A3 (en) | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases | |
DE59904564D1 (de) | Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien | |
ATE390920T1 (de) | Lipase inhibitoren zur behandlung von dyspepsia | |
HK1062806A1 (en) | Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors | |
DE50003481D1 (de) | Verwendung von schmutzablösenden formulierungen zur behandlung von oberflächen | |
SI1363910T1 (sl) | Postopki zdravljenja s P38 kinazo povezanih stanjin pirolotriazinske spojine, uporabne kot inhibitorji kinaze | |
DE60124373D1 (de) | Verwendung von enoxaparin zur behandlung der zerebralen ischämie | |
DK1335730T3 (da) | Anvendelse af PDE5-inhibitorer til behandling af ejaculatio praecox | |
AU2002342650A1 (en) | Nitrogen-containing heterocyclic compounds and their use as raf inhibitors |